Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 63 results
Filters: Author is Kuritzkes, Daniel R  [Clear All Filters]
Found 63 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

E

Andrade A, Guedj J, Rosenkranz SL, et al. "Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)." AIDS. 2015;29(18):2419-26.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Hu Z, Kuritzkes DR. "Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness." J. Acquir. Immune Defic. Syndr.. 2010;55(2):148-55.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Gallien S, Delaugerre C, Charreau I, et al. "Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia." AIDS. 2011;25(5):665-9.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.

Pages